| Cardiovascular Risk Management |
1 |
1 |
| Biliary Disease |
0 |
0.9 |
| Non-Alcoholic Fatty Liver Disease |
0 |
0.95 |
| Liver |
0 |
0.99 |
| Aminotransferase |
0 |
0.59 |
| Cirrhosis |
0 |
0.98 |
| Liver Biopsy |
0 |
0.54 |
| Metabolic Syndrome |
0 |
0.44 |
| Thyroid |
0 |
0.24 |
| Thyroid Disease |
0 |
0.24 |
| Lipids Management |
0 |
0.19 |
| Biopsy |
0 |
0.15 |
| Metabolism |
0 |
0.15 |
| Receptors |
0 |
0.15 |
| Spleen |
0 |
0.15 |
| Hypertension |
0 |
0.08 |
| Beta Blockers |
0 |
0.05 |
| Biomarker |
0 |
0.05 |
| Blood |
0 |
0.05 |
| Bone |
0 |
0.05 |
| Clinical Research |
0 |
0.05 |
| Fatty Acids |
0 |
0.05 |
| Healthcare and Medical Technology |
0 |
0.05 |
| Hospital |
0 |
0.05 |
| Nausea |
0 |
0.05 |
| Nonalcoholic Steatohepatitis |
0 |
0.05 |
| Pharmacokinetics |
0 |
0.05 |
| Portal Hypertension |
0 |
0.05 |